Device Trial Radar · NCT01708213
Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device
Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- TauTona GroupNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 16, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The protocol hypothesis is that treatment with Aline HA™ will be safe through 6 months as determined by clinical assessment of treatment sites and routine tracking of adverse events.
Conditions
- Disorder of Soft Tissue
Interventions
Aline HADevice
Implantable dermal filler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Treatment Site Responses Post ProcedureTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dr. Nowell Solish
Toronto, Ontario, Canada
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.